Bluestar Adisseo Company (600299) Fair Value & Analysis
Basic Materials · CN · Market cap 31.3B CNY
Analysis
Bluestar Adisseo Company (600299) currently trades at ¥9.56, while our model-based Fair Value estimate is ¥6.07 — implying the stock looks roughly 36.5% overvalued today. We read business quality at 95/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Bluestar Adisseo Company, together with its subsidiaries, engages in the research, development, production, and sale of poultry, ruminant, swine, and aquaculture nutrition additives. The company also offers mycotoxin management and palatability comprising, Unike Plus, Unike, Oxy-Nil, Mold-Nil, Salmo-Nil, Toxy-Nil, Krave AP, Optisweet, Gusti Plus, Maxarome, Delistart, Pepsea, Nutri-Bind Aqua, and Oxy-Nil Aqua Zero; enzymes and emulsifiers, including Rhodimet AT88 and Rhodimet; antioxidants and health by nutrition products, comprising Rhodimet AT88, Rhodimet NP99, Microvit A Supra 1000, and Microvit E Promix 50; milk production product, such as MetaSmart; and sulfur-based products, which includes Rhodimet AT88, Rhodimet® NP99, Microvit A Supra 1000, and Microvit E Promix 50. In addition, the company offers mycotoxin management products, such as Unike Plus, Unike, Toxy-Nil, Krave AP, Optisweet, Gusti Plus, Maxarome, and Delistart, as well as essential nutrient products, such as Rhodime…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.